866-997-4948(US-Canada Toll Free)

Kidney Transplantation Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 127 Pages


Global Markets Directs, \'Kidney Transplantation Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Kidney Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Transplantation. 

Kidney Transplantation Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Kidney Transplantation.
  • A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Kidney Transplantation pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Kidney Transplantation.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Kidney Transplantation pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Kidney Transplantation Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Kidney Transplantation 10
Kidney Transplantation Therapeutics under Development by Companies 12
Kidney Transplantation Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Pre-Clinical Stage Products 19
Comparative Analysis 19
Kidney Transplantation Therapeutics Products under Development by Companies 20
Kidney Transplantation Therapeutics Products under Investigation by Universities/Institutes 22
Companies Involved in Kidney Transplantation Therapeutics Development 23
Kyowa Hakko Kirin Co., Ltd. 23
Amgen Inc. 24
Quark Pharmaceuticals, Inc. 25
Pharming Group N.V. 26
Isotechnika Pharma Inc. 27
Astellas Pharma Inc. 28
ViroPharma Incorporated 29
4SC AG 30
LifeCycle Pharma A/S 31
La Jolla Pharmaceutical Company 32
Alexion Pharmaceuticals, Inc. 33
Portola Pharmaceuticals, Inc. 34
Hansa Medical AB 35
Biotecnol SA 36
Palau Pharma S.A 37
Opsona Therapeutics Ltd. 38
Angion Biomedica Corp. 39
TcL Pharma SAS 40
Tolera Therapeutics, Inc. 41
Nephrx Corporation 42
Kidney Transplantation Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
ASKP-1240 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
cinacalcet hydrochloride - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
voclosporin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Cardiotrophin-1 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
vidofludimus - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
tacrolimus ER - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
eculizumab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
conestat alfa - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BB-3 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
FR-104 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
QPI-1002 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
GCS-100 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
TOL-101 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
tacrolimus - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
NX-001 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
alemtuzumab + [tacrolimus] - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
conestat alfa - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
JAK3 Program - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
OPN-305 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Jak3/Syk Dual Inhibitor - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
LJPC-101 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
IdeS - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Kidney Transplantation Therapeutics Drug Profile Updates 89
Kidney Transplantation Therapeutics Discontinued Products 117
Kidney Transplantation Therapeutics - Dormant Products 118
Kidney Transplantation Product Development Milestones 119
Featured News & Press Releases 119
Nov 12, 2012: Pfizer Provides Update On Its Rapamune Settlement 119
Oct 17, 2012: University Of Cincinnati Receives $2.7m FDA Grant To Study Generic Versus Brand-Name Transplant Drugs 119
Oct 10, 2012: Veloxis Pharma To Present Data Differentiating LCP-Tacro From Available Tacrolimus Formulations At Transformational Therapies And Diagnostics In Transplantation Conference 120
Sep 24, 2012: Astellas Submits New Drug Application For Tacrolimus Extended Release Capsules 121
Jun 28, 2012: 3SBio Obtains SFDA Approval To Join Global Phase III Trial For Voclosporin 121
May 31, 2012: Veloxis To Present Results From Patient Subgroup Analysis Of LCP-Tacro In Kidney Transplant Patients At American Transplant Congress 121
May 23, 2012: Veloxis To Restructure Operations For Strengthening Strategic Focus On LCP-Tacro 123
Mar 29, 2012: Veloxis Pharmaceuticals Completes Enrolment In LCP-Tacro 3002 Pivotal Phase III Trial In Kidney Transplant 123
Mar 14, 2012: Hansa Medical Receives Patents In US And Europe For Medical Use Of IdeS 124
Mar 12, 2012: Isotechnika Enters Agreement With FDA On Special Protocol Assessment For Phase III Voclosporin Trial 124

Appendix 126
Methodology 126
Coverage 126
Secondary Research 126
Primary Research 126
Expert Panel Validation 126
Contact Us 127
Disclaimer 127

List of Table


Number of Products Under Development for Kidney Transplantation, H1 2013 10
Products under Development for Kidney Transplantation Comparative Analysis, H1 2013 11
Number of Products under Development by Companies, H1 2013 13
Number of Products under Development by Companies, H1 2013 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2013 15
Comparative Analysis by Late Stage Development, H1 2013 16
Comparative Analysis by Mid Clinical Stage Development, H1 2013 17
Comparative Analysis by Early Clinical Stage Development, H1 2013 18
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Development by Companies, H1 2013 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2013 22
Kyowa Hakko Kirin Co., Ltd., H1 2013 23
Amgen Inc., H1 2013 24
Quark Pharmaceuticals, Inc., H1 2013 25
Pharming Group N.V., H1 2013 26
Isotechnika Pharma Inc., H1 2013 27
Astellas Pharma Inc., H1 2013 28
ViroPharma Incorporated, H1 2013 29
4SC AG, H1 2013 30
LifeCycle Pharma A/S, H1 2013 31
La Jolla Pharmaceutical Company, H1 2013 32
Alexion Pharmaceuticals, Inc., H1 2013 33
Portola Pharmaceuticals, Inc., H1 2013 34
Hansa Medical AB, H1 2013 35
Biotecnol SA, H1 2013 36
Palau Pharma S.A, H1 2013 37
Opsona Therapeutics Ltd., H1 2013 38
Angion Biomedica Corp., H1 2013 39
TcL Pharma SAS, H1 2013 40
Tolera Therapeutics, Inc., H1 2013 41
Nephrx Corporation, H1 2013 42
Assessment by Monotherapy Products, H1 2013 43
Assessment by Combination Products, H1 2013 44
Assessment by Stage and Route of Administration, H1 2013 46
Assessment by Stage and Molecule Type, H1 2013 48
Kidney Transplantation Therapeutics Drug Profile Updates 89
Kidney Transplantation Therapeutics Discontinued Products 117
Kidney Transplantation Therapeutics Dormant Products 118

List of Chart


Number of Products under Development for Kidney Transplantation, H1 2013 10
Products under Development for Kidney Transplantation Comparative Analysis, H1 2013 11
Products under Development by Companies, H1 2013 12
Products under Investigation by Universities/Institutes, H1 2013 15
Late Stage Products, H1 2013 16
Mid Clinical Stage Products, H1 2013 17
Early Clinical Stage Products, H1 2013 18
Pre-Clinical Stage Products, H1 2013 19
Assessment by Monotherapy Products, H1 2013 43
Assessment by Combination Products, H1 2013 44
Assessment by Route of Administration, H1 2013 45
Assessment by Stage and Route of Administration, H1 2013 46
Assessment by Molecule Type, H1 2013 47
Assessment by Stage and Molecule Type, H1 2013 48

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *